For instance, the use of the CRISPR/Cas9 system in organoids to correct mutations in the CFTR gene causing cystic fibrosis, has also demonstrated that it is possible to use a similar strategy to generate autologous organoids for transplantation in patients [13]. This evidence concerns the gene CFTR and cystic fibrosis.